FORX-428: A Novel, Potent PARG Inhibitor Demonstrating Strong Anti- Tumor Activity in Preclinical Cancer Models
Time: 8:00 am
day: Day Two
Details:
- Reviewing the rationale for targeting PARG to selectively treat cancers with deficiencies in DNA repair
- Assessing the characteristics of FORX-428, emphasizing its potency, selectivity, and promising efficacy in various cancer models
- Uncovering the for advancing FORX-428 to clinical trials for cancer therapy
